pfizer的武汉基地# Returnee - 海归
T*R
1 楼
April 26 (Bloomberg) -- Charles River Laboratories International Inc. agreed
to buy WuXi PharmaTech (Cayman) Inc. for about $1.6 billion to expand in
China, where revenue from drug-testing services is growing as much as 30
percent a year.
Charles River will pay $21.25 a share, comprising $11.25 in cash and $10 in
stock, for each WuXi American depositary share, the companies said in a
statement today. The offer is 28 percent more than WuXi’s closing price of
$16.57 in New York Stock Exchange trad
to buy WuXi PharmaTech (Cayman) Inc. for about $1.6 billion to expand in
China, where revenue from drug-testing services is growing as much as 30
percent a year.
Charles River will pay $21.25 a share, comprising $11.25 in cash and $10 in
stock, for each WuXi American depositary share, the companies said in a
statement today. The offer is 28 percent more than WuXi’s closing price of
$16.57 in New York Stock Exchange trad